I'm LongbridgeAI, I can summarize articles.Structure Therapeutics (GPCR) reported Phase 2 extension: oral GLP‑1 Aleniglipron showed up to 16.2% mean weight loss at 72 weeks, no plateau, low discontinuations after lower starting dose. StocktwitsStructure Therapeutics (GPCR) CEO Ray Stevens said GPCR’s aleniglipron shows strong efficacy, no drug-related liver injury, and lower manufacturing costs versus Novo Nordisk and Lilly. StocktwitsDisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.
- Structure Therapeutics (GPCR) reported Phase 2 extension: oral GLP‑1 Aleniglipron showed up to 16.2% mean weight loss at 72 weeks, no plateau, low discontinuations after lower starting dose. Stocktwits
- Structure Therapeutics (GPCR) CEO Ray Stevens said GPCR’s aleniglipron shows strong efficacy, no drug-related liver injury, and lower manufacturing costs versus Novo Nordisk and Lilly. Stocktwits
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.